fenofibrate has been researched along with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Cheng, L; Chi, W; Deng, H; Feng, Y; Ge, M; Hu, X; Huang, Y; Huo, Y; Kuang, W; Lan, Z; Li, L; Liu, X; Liu, Y; Luo, M; Ma, Z; Siegenthaler, JA; Sun, K; Xi, Q; Xu, L; Yang, J; Zhang, B; Zhang, Y; Zhao, X | 1 |
1 other study(ies) available for fenofibrate and 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide
| Article | Year |
|---|---|
Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.
Topics: Animals; Benzamides; Cell Line; Coenzyme A Ligases; Dioxoles; Epithelial Cells; Fatty Acids; Fenofibrate; Fibrosis; Humans; Kidney Diseases; Kidney Tubules; Lipid Metabolism; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Oxidation-Reduction; Transforming Growth Factor beta; Zoledronic Acid | 2018 |